Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CHEMOTHERAPY AND CARDIOTOXICITY
Autore:
BRESTESCHER C; PAUTIER P; FARGE D;
Indirizzi:
HOP ST LOUIS,SERV MED INTERNE & PATHOL VASC,1 AVE CLAUDE VELLEFAUX F-75010 PARIS FRANCE
Titolo Testata:
Annales de cardiologie et d'angeiologie
fascicolo: 8, volume: 44, anno: 1995,
pagine: 443 - 447
SICI:
0003-3928(1995)44:8<443:CAC>2.0.ZU;2-X
Fonte:
ISI
Lingua:
FRE
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
NO
Recensione:
Indirizzi per estratti:
Citazione:
C. Brestescher et al., "CHEMOTHERAPY AND CARDIOTOXICITY", Annales de cardiologie et d'angeiologie, 44(8), 1995, pp. 443-447

Abstract

Among the various anticancer drugs, used alone or in combination during courses of chemotherapy, anthracyclines (leader: doxorubicin) are responsible for direct myocardial toxicity, which can exceptionally be acute, but more often chronic with a delayed onset. This cardiotoxicity is directly proportional to the cumulative dose administered and therecommended total dose for doxorubicin is 550 mg/m(2). The risk factors able to potentiate cardiotoxicity must be analysed before starting chemotherapy and follow-up by ultrasonography and/or isotope ejection fraction must be repeated before each course. The treatment of anthracycline-induced heart failure consists of digitalis alkaloids combined with angiotensin converting enzyme inhibitors. The cardiac toxicity of5FU is currently explained by the theory of coronary spasm, based on clinical findings such as chest pain associated with ischaemic electrical modifications. The incidence of this toxicity is low, but it can be fatal. Exceptional examples include the cardiotoxicity induced by high-dose cyclophosphamide responsible for acute haemorrhagic myocarditis, potentiation of the cardiotoxic effect of anthracyclines by dacarbazine and plicamycin, and serious ventricular and supraventricular arrhythmias induced by amsacrine. Among the various cytokines used in oncology, interferon is responsible for heart failure, reversible after stopping treatment, but also for ventricular arrhythmias, or even suddendeath, the pathophysiology of which still remains unclear.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 14:23:40